Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo-associated paraneoplastic cerebellar degeneration
Authors:
- Iñigo Rojas-MarcosIRIñigo Rojas-Marcos
- Geraldine PicardGPGeraldine Picard
- David ChinchónDCDavid Chinchón
- Ellen GelpiEGEllen Gelpi
- Dimitri PsimarasDPDimitri Psimaras
- Bruno GiomettoBGBruno Giometto
- J. Y. DelattreJDJ. Y. Delattre
- J. HonnoratJHJ. Honnorat
- F. GrausFGF. Graus
Open Access
- 20 February 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 14 (4) , 506-510
Abstract
Isolated case reports suggest that breast tumors from patients with paraneoplastic cerebellar degeneration (PCD) and Yo antibodies overexpress human epidermal growth factor receptor 2 (HER2). HER2 overexpression is present in 15%–25% of breast cancers and is associated with poor prognosis. We retrospectively analyzed the status of HER2 in breast tumors of 27 patients with anti-Yo–associated PCD to evaluate whether HER2 overexpression in this group of patients is higher than expected. In addition, we analyzed HER2 status of 19 breast tumors from patients with paraneoplastic neurological syndromes and Ri antibodies to see whether HER2 was specifically related to anti-Yo–associated PCD. We also assessed cdr2 expression (the onconeural antigen recognized by Yo antibodies) in 21 HER2-positive breast tumors from patients without paraneoplastic neurological syndromes. HER2 was overexpressed in 26 patients (96.3%) with anti-Yo–associated PCD but only in 2 patients (10.5%) with paraneoplastic neurological syndromes associated with Ri antibodies (P< .0001). Only 5 (23.8%) of the 21 HER2-positive breast tumors showed cdr2 immunoreactivity. This study shows a very high frequency of HER2 overexpression in breast cancers in patients with anti-Yo–associated PCD but not in those from patients with Ri antibodies. Although the expression of cdr2 onconeural antigen is not high in HER2-positive breast cancers, HER2 overexpression seems to be an important requirement to develop an anti-Yo–associated PCD.Keywords
This publication has 23 references indexed in Scilit:
- CDR2 antigen and Yo antibodiesCancer Immunology, Immunotherapy, 2010
- Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle BiopsiesJournal of Clinical Oncology, 2010
- Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of OutcomeJournal of Clinical Oncology, 2010
- Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibody in a Patient with HER2neu Overexpressing Breast Cancer: A Case Report with a Current Literature ReviewThe Breast Journal, 2008
- High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence RatesCancer Research, 2007
- HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 PatientsPLOS ONE, 2007
- Paraneoplastic Syndromes Involving the Nervous SystemNew England Journal of Medicine, 2003
- Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings.American Journal of Roentgenology, 1998
- Paraneoplastic cerebellar degeneration.Neurology, 1992
- Selective Expression of Purkinje-Cell Antigens in Tumor Tissue from Patients with Paraneoplastic Cerebellar DegenerationNew England Journal of Medicine, 1990